Market Overview

Markets are trading mixed-to-lower this morning as a stronger-than-expected May jobs report is pushing yields higher, weighing on growth/tech names while supporting financials and defensive sectors. Broadcom’s revenue miss overnight is dragging semiconductors, creating a notable rotation into insurance, healthcare, and travel/leisure names. The SpaceX IPO buzz (targeting $135/share next Friday) is adding speculative energy but also sucking oxygen from other growth stories.

Top Movers

IOT (+10.1%) — $36.76 → $40.00 (+8.8% upside) Thesis: Samsara beat Q1 EPS by 27% ($0.17 vs $0.13 est) and revenue by 5%, with ARR growing 30% to $1.99B — but the stock is rallying despite underwhelming Q2 guidance that’s merely “in line.” This is a classic beat-and-guide-sideways setup where the initial pop often fades. With RSI at a deeply oversold 16.5, this looks like a relief rally from a massively beaten-down level rather than a sustainable breakout. The stock was clearly priced for disaster heading in, and it didn’t get one. Levels: Exit at $40 (prior consolidation zone). Support at $33.50 (pre-earnings close).

GIII (+7.5%) — $34.40 → $38.00 (+10.5% upside) Thesis: G-III beat revenue by 1% and narrowed its loss to -$0.21 vs -$0.30 expected (+30% beat) while guiding Q2 revenue 2.7% above consensus at $570M midpoint. The Marc Jacobs acquisition narrative gives this a longer-term catalyst beyond the PVH brand wind-down. RSI at 12.1 screams deeply oversold — this was a hated name getting a legitimate positive inflection. The transition story from licensed brands to owned brands (Karl Lagerfeld, DKNY, Marc Jacobs) is becoming investable. Levels: Exit at $38 (200-day area). Support at $32 (pre-earnings level).

ARCB (+6.1%) — $155.23 → $170.00 (+9.5% upside) Thesis: ArcBest is riding a multi-day move (+13.6% on the week) driven by the crude oil crash to $92.94 providing direct fuel cost relief plus the ArcBest View platform launch giving a digital narrative. This is a genuine fundamental tailwind — lower diesel costs flow directly to LTL margins — but at RSI 50 and already up big on the week, the easy money may be made. Still, if oil stays down, there’s more room. Levels: Exit at $170 (prior swing high zone). Support at $145 (pre-rally breakout level).

SHG (+5.8%) — $68.43 → $72.00 (+5.2% upside) Thesis: Shinhan Financial is benefiting from the rising yield environment (jobs report pushing rates higher) plus its Value Up 3.0 program emphasizing higher ROE and shareholder returns. Korean financials remain cheap globally, and the dividend yield story resonates in a risk-off rotation. Sector sympathy with the broader “financials outperform when yields rise” playbook. Levels: Exit at $72 (52-week high area). Support at $64.50 (20-day MA zone).

GKOS (+5.7%) — $127.38 → $151.00 (+18.5% upside) Thesis: Glaukos continues its post-Q1 run (+23% this week) after demolishing estimates with 41% revenue growth and raising 2026 guidance. The updated fair value estimate of $151 from analysts provides a clear target. At RSI 54, this still has technical room before becoming overbought. The iStent and corneal health story is a genuine secular growth narrative in a medical device space that’s bouncing broadly. Levels: Exit at $151 (updated analyst fair value). Support at $115 (post-earnings gap fill).

CI (+3.2%) — $286.92 → $305.00 (+6.3% upside) Thesis: Cigna is riding the managed-care sector rally after Morgan Stanley highlighted softer medical cost trends and AI efficiency upside for the big MCOs. This is a legitimate fundamental catalyst — lower medical loss ratios are the single biggest earnings driver for insurers — not just sector sympathy. UNH +5%, HUM +6% yesterday means CI is actually lagging its peers and has catch-up potential. Levels: Exit at $305 (prior resistance). Support at $275 (50-day MA).

ABM (+4.6%) — $41.76 → $45.00 (+7.8% upside) Thesis: ABM beat revenue by 3% with 8.4% YoY growth and reported record first-half new sales bookings, while maintaining full-year guidance. RSI at an absurd 4.2 means this stock was catastrophically oversold — any positive news was going to spark a violent bounce. The slight EPS miss (-2%) is being completely ignored in favor of the revenue beat and forward booking strength. This is a textbook mean-reversion trade. Levels: Exit at $45 (50-day MA area). Support at $39.50 (yesterday’s close).

INCY (+4.3%) — $105.64 → $115.00 (+8.9% upside) Thesis: Incyte is surging on the tafasitamab Phase 3 frontMIND win in first-line DLBCL, featured at ASCO 2026 and published in The Lancet — this is a legitimate pipeline catalyst that could move the drug from later-line to frontline treatment. JPMorgan’s recent call that “large-cap biotech is back” provides sector tailwinds. This is real news with regulatory filing catalysts ahead. Levels: Exit at $115 (prior resistance and analyst target zone). Support at $100 (round number/psychological level).

HLT (+3.7%) — $345.94 → $360.00 (+4.1% upside) Thesis: Hilton is riding the travel/leisure rotation sparked by the oil price crash (cheaper travel costs) plus sector-wide Goldman upgrades on timeshare companies. The “Undergraduate by Hilton” brand launch targeting college markets shows pipeline innovation. However, at RSI 66.6 and near 52-week highs, this is the most extended name in the travel cluster today — the risk/reward is less attractive than peers. Levels: Exit at $360 (fib extension zone). Support at $333 (20-day MA).

ALL (+3.1%) — $217.17 → $230.00 (+5.9% upside) Thesis: Allstate is bouncing with the entire P&C insurance sector (CB +3.1%, HCI +4.4%) on rising yields making investment portfolios more profitable and the general defensive rotation. April cat losses of $870M were digested last month — the stock is now in “show me improvement” mode. Piper Sandler’s undervalued call from late May is getting traction. The setup is a value recovery in a sector benefiting from the macro backdrop. Levels: Exit at $230 (prior high). Support at $205 (recent swing low).

Headlines to Watch

  • May Jobs Report Surprises to the Upside — Yields climbing, which explains the financials/insurance strength and tech weakness today; watch for Fed rate cut expectations to get pushed further out.
  • Broadcom Revenue Miss Sparks Chip Sector Pullback — AVGO weakness is dragging semis; this creates potential buy-the-dip setups in MU/MRVL if the selling is overdone, but validates the rotation into non-tech.
  • SpaceX IPO Priced at $135, Trading Next Friday June 12 — S&P confirms no fast-track to index inclusion; this will absorb massive capital from growth investors and could create liquidity headwinds for other high-growth names.
  • Morgan Stanley Bullish on Managed Care (UNH, CI, CVS) — Softer medical utilization trends + AI efficiency upside is a powerful combination; MCO names could run for weeks on this theme.
  • Oil Crashes 4.7% to $92.94 on Iran-US Peace Deal Progress — Direct margin relief for transports (ARCB), airlines, and consumer discretionary while hurting energy names; watch if this holds.
  • Lululemon Plunges on Outlook Cut — Despite WSB bullishness (80%), the guidance cut is a real fundamental deterioration; be cautious of “buy the dip” calls on broken growth stories.
  • Taiwan ETF +62% YTD vs S&P 500 +11% — International outperformance continues; semiconductor supply chain exposure driving massive outperformance that may have further room given AI capex cycle.

Claude’s Top Picks

GIII (+7.5% today, +6.4% week) — $34.40 → $38.00 (+10.5% upside) Valuation: At ~0.4x EV/Revenue with improving margins and an owned-brand transition, GIII is dirt cheap vs. apparel peers like PVH (1.2x) and Tapestry (2.5x) — the Marc Jacobs acquisition gives it a luxury optionality the market hasn’t priced. Upside: Record-low RSI of 12, revenue beat + raised guidance, and a clear narrative shift from “losing PVH licenses” to “building a brand portfolio” — the re-rating story is just starting. Risk: Consumer discretionary weakness if the strong jobs report paradoxically tightens financial conditions further; the PVH transition still has execution risk through FY27.

ABM (+4.6% today, +6.9% week) — $41.76 → $45.00 (+7.8% upside) Valuation: Trading at ~12x forward earnings vs. facility services peers at 15-18x, with 8.4% revenue growth — this is genuinely cheap for a company reporting record bookings. Upside: RSI at 4.2 is one of the most oversold readings I’ve seen in any liquid stock; the revenue beat and record bookings provide fundamental justification for a violent mean-reversion back toward the 50-day MA. Risk: The slight EPS miss (-2%) and only maintaining (not raising) full-year guidance could cap enthusiasm if the bounce stalls at technical resistance.

INCY (+4.3% today, +9.2% week) — $105.64 → $115.00 (+8.9% upside) Valuation: At ~15x forward earnings with a blockbuster pipeline catalyst (tafasitamab first-line DLBCL), INCY is cheap vs. large-cap biotech peers averaging 18-20x; JPMorgan just called large-cap biotech “back.” Upside: Phase 3 win at ASCO with Lancet publication is the highest-quality clinical catalyst possible; regulatory filings globally create a multi-quarter event path that institutional investors will accumulate into. Risk: Regulatory timelines can slip, and tafasitamab already has some revenue contribution — the market may be partially pricing in first-line expansion already.

CI (+3.2% today, +4.0% week) — $286.92 → $305.00 (+6.3% upside) Valuation: At ~11x forward earnings vs. UNH at 18x and HUM at 14x, Cigna remains the cheapest large-cap MCO despite similar exposure to the softer utilization trends Morgan Stanley highlighted. Upside: CI lagged UNH (+5%) and HUM (+6%) yesterday — classic catch-up trade in a sector where the fundamental catalyst (lower MLR) is real and ongoing, not a one-day event. Risk: Any reversal in medical cost trends (new COVID variant, seasonal flu spike) would immediately compress the group; CI’s PBM business (Express Scripts) faces ongoing political scrutiny.

CON (+4.9% today, +3.5% week) — $25.75 → $30.00 (+16.5% upside) Valuation: Analysts see 25% upside to $30+ targets after the Q1 earnings beat and raised 2026 guidance; trading at a discount to occupational health peers with a dividend and active buyback. Upside: RSI at 7.3 is absurdly oversold with real catalysts (earnings beat, guidance raise, dividend, buybacks) — Wall Street consensus target implies significant upside from current levels. Risk: Small-cap healthcare services name with limited liquidity; if broader market sells off on the hot jobs report, illiquid names get hit hardest.

Avoid

HLT (+3.7%) — At $345.94 with RSI 66.6, Hilton is the most extended name in today’s travel cluster. Near 52-week highs with skeptical analyst coverage (“3 High-Flying Stocks We’re Skeptical Of” literally referenced it yesterday), the risk/reward here is poor for new entries. Let it pull back to $330.

TNDM (+5.0%, +17.2% week) — Tandem Diabetes has ripped 17% in a week on a Wells Fargo upgrade and RSI is already at 62.6. The pharmacy channel shift is real but the stock at 1.1x forward sales has already moved to reflect it. Chasing a 17% weekly gainer without a new catalyst today is how you become exit liquidity.

ZIM (+3.2%) — Despite Cramer saying “I would buy some,” ZIM just reported a wider-than-expected Q1 loss and missed revenues. The Hapag-Lloyd acquisition creates binary event risk. You’re buying a money-losing shipper with takeover uncertainty at the whim of geopolitical Hormuz headlines. This is a trade, not an investment, and the easy money on the oil-crash sympathy move was yesterday.

WSB Sentiment Check

MU — WSB says: MIXED (55% bullish) Claude says: PARTIALLY AGREE — Micron benefits from the AI memory demand cycle, but with AVGO missing and semis pulling back today, the near-term setup is choppy. The mixed WSB sentiment actually feels appropriate here — this isn’t a high-conviction long until the sector digests the Broadcom miss. Wait for $115-120 support.

AVGO — WSB says: BEARISH (30% bullish) Claude says: AGREE — Broadcom’s revenue miss is the direct catalyst dragging chips today and WSB is right to be cautious near-term. However, this is likely overdone on a 1-2 week basis for a company with dominant AI networking exposure. WSB is correct directionally today but could be wrong in a week. Watch for $180 support as a potential entry.

LULU — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — WSB is delusional here. Lululemon literally just cut guidance and is “plunging” today per multiple headlines. Buying a broken growth story after a guidance cut because “it’s cheap now” is peak WSB behavior. The company is telling you the business is deteriorating — listen to management, not the Reddit hive mind. Avoid until $350 support is tested.

MRVL — WSB says: BEARISH (30% bullish) Claude says: PARTIALLY AGREE — Marvell catches the Broadcom contagion as a fellow custom AI chip play, and near-term sentiment is rightfully cautious. But Marvell’s own earnings were solid and its custom silicon pipeline (Amazon, Microsoft) is differentiated. If this pulls back 5-8% on pure sympathy, it becomes interesting. WSB bearishness may be a contrarian buy signal on weakness.

MSFT — WSB says: BEARISH (30% bullish) Claude says: DISAGREE — Microsoft at $500+ with Azure growing 30%+, Copilot monetizing, and gaming/LinkedIn contributing is not a short. WSB is bearish because it hasn’t moved as much as the hyper-growth AI names — that’s called being fairly valued, not broken. MSFT is a core holding, not a trade. Betting against the largest AI capex spender (behind Google) is brave but likely wrong on any 3+ month horizon.

Earnings Scorecard

IOT — BEAT by 27% (EPS) and 5% (Revenue) | Stock: +10.1% | Reported: Thursday After Close The reaction is justified given the stock was trading at RSI 16 — deeply oversold with expectations set absurdly low. However, Q2 guidance being merely “in line” means this is a relief rally, not a fundamental re-rate. The +10% move prices in the beat fairly. Sell-the-rip above $40 unless Q2 guidance gets raised on the call; hold if you bought the pre-earnings dip.

GIII — BEAT by 30% (EPS) and 1% (Revenue) | Stock: +7.5% | Reported: Thursday After Close Reaction is warranted — the beat plus above-consensus Q2 guidance at $570M signals the PVH transition is going better than feared. The Marc Jacobs acquisition narrative adds a longer-term catalyst. With RSI at 12 pre-report, this stock was priced for bankruptcy, not a beat. Still a buy-the-dip at $32-33 if it pulls back.

ABM — MIXED: Revenue beat +3%, EPS miss -2% | Stock: +4.6% | Reported: Thursday After Close Market is correctly focusing on the revenue beat and record bookings rather than the marginal EPS miss. Maintaining (not cutting) full-year guidance after a slight miss is actually reassuring. At RSI 4.2, literally any non-catastrophic result was going to spark a bounce. The reaction is rational — hold for mean-reversion to the 50-day MA near $45.

TTAN — REPORTED | Stock: -5.8% Selling into a broad market up-day suggests the results disappointed, though specific numbers aren’t available. Without details, this is a “stay away until the dust settles” situation.